New hope for kidney transplant patients: drug shows promise in fighting rejection Long-Term
NCT ID NCT07444489
First seen Mar 05, 2026 · Last updated May 09, 2026 · Updated 8 times
Summary
This study looks at the long-term safety and effects of a drug called felzartamab in people who have had a kidney transplant and later developed antibody-mediated rejection (AMR). AMR occurs when the body's immune system attacks the new kidney. Participants who completed an earlier study can join this one and receive felzartamab for up to 4 more years. The goal is to monitor side effects, kidney health, and overall outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cooperman Barnabas Medical Center
West Orange, New Jersey, 07039, United States
-
UCLA College of Medicine
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.